[DLys6]GnRH-4EBP1-WT

**[DLys6]GnRH-4EBP1-WT** is a synthetic fusion peptide that combines an analog of gonadotropin-releasing hormone ([DLys6]GnRH) with a peptide derived from residues 49–68 of the eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1). This design allows for selective delivery to tumor cells overexpressing GnRH receptor type 1 (GnRH-R1), frequently found in ovarian and other endocrine-related cancers. The 4EBP1 segment binds to eIF4E and blocks its interaction with eIF4G, thereby inhibiting cap-dependent translation and tumor cell proliferation. The GnRH segment enables receptor-mediated cell targeting and uptake. In preclinical studies, the peptide demonstrated inhibition of cap-dependent translation and significant tumor growth reduction specifically in cells expressing GnRH-R1[1].

Other names

[DLys6]GnRH‐4EBP1‐WT